Pepsin A

Pepsin A is a major gastric digestive enzyme responsible for the breakdown of dietary proteins into peptides, facilitating absorption. It is secreted by gastric chief cells as the inactive precursor pepsinogen, which is activated in the stomach at an acidic pH (1.5–2.5) through cleavage into its active form. The secretion of pepsinogen is stimulated by acetylcholine, gastrin, and low gastric pH.

Pepsin A primarily cleaves peptide bonds adjacent to aromatic amino acids such as phenylalanine, tryptophan, and tyrosine. Beyond its role in digestion, pepsin A has important clinical significance in extra-esophageal reflux disease. In laryngopharyngeal reflux (LPR), reflux of gastric contents including acid and pepsin into the pharynx and larynx leads to epithelial injury, chronic inflammation, and symptomatic manifestations such as hoarseness, chronic cough, globus sensation, throat clearing, and dysphagia. Persistent exposure has been implicated in mucosal damage, metaplasia, and potentially malignant transformation.

Measurement of pepsin A in tracheal or bronchial fluid serves as a biomarker for extra-esophageal reflux, aiding in the evaluation of LPR, GERD, and Barrett’s esophagus, and complements clinical and endoscopic evaluation.

  • Non-invasive biomarker for monitoring laryngopharyngeal reflux and GERD
  • Adjunctive test for the evaluation and monitoring of Barrett’s esophagus
  • Assessment of airway and esophageal injury related to reflux

Increased in:

  • Gastroesophageal reflux disease
  • Laryngopharyngeal reflux disease
  • Peptic ulcer disease
  • Gastritis
  • Esophageal and gastric cancer
  • Hiatal hernia

Decreased in:

  • Achlorhydria
  • Hypochlorhydria
  • Atrophic gastritis
  • Gastrectomy
  • Cystic fibrosis
  • Pancreatic insufficiency

Negative: <12.5

Weak to moderate positive: 12.5 – 100

>100 strong positive

Chemiluminescent immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).

Tracheal or bronchial fluid, 1 mL transported in standard transport tube.

Stability

  • Frozen: 30 days
Stomach biopsy, gastric parietal cell antibody IgG, serum gastrin, pepsinogen I, pepsinogen II, comprehensive metabolic panel.
3 to 7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Otolaryngol Head Neck Surg. 2017 Sep;157(3):385-391. [PMID: 28585488]
  • Laryngoscope. 2020 Jul;130(7):1780-1786. [PMID: 31603541]
  • Eur Ann Otorhinolaryngol Head Neck Dis. 2021 Sep;138(4):257-267. [PMID: 33257265]
  • 2022 Dec 19. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. [PMID: 30137832]